Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06438055

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Tianjin Medical University Cancer Institute and Hospital · Academic / Other
Sex
Female
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study aims to enroll refractory breast cancer patients. Patient-derived organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.

Detailed description

Forty patients with refractory breast cancer who met the inclusion criteria were enrolled in the study after signing an informed consent form. Tumor samples were obtained through clinical puncture, and qualified samples were subjected to organoid modeling. Perform drug sensitivity test on the established breast cancer organoids. The drugs used are all that have been marketed and applied in clinical practice. According to the results of organoid drug sensitivity analysis, the patient received a treatment plan with relatively sensitive drugs. Follow up prognostic data and relevant clinical information of enrolled patients, conduct statistical analysis on the consistency between drug sensitivity test results and patient treatment response, and evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity results.

Conditions

Interventions

TypeNameDescription
OTHERChemotherapy and targeted-therapy guided by organoid drug sensitivity testThis study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.

Timeline

Start date
2024-06-01
Primary completion
2025-06-01
Completion
2026-06-01
First posted
2024-05-31
Last updated
2024-05-31

Source: ClinicalTrials.gov record NCT06438055. Inclusion in this directory is not an endorsement.